Clindamycin is a lincosamide antibiotic. It inhibits bacterial protein synthesis by binding to the 50s subunit of the ribosome. It has activity against Gram-positive aerobes and anaerobes as well as the gram-negative anaerobes. Clindamycin is indicated for Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess caused by Anaerobes. It is also indicated for Serious respiratory tract infections, serious skin and soft tissue infections caused by streptococci and staphylococci: Serious respiratory tract infections caused by Pneumococci.
- Shows excellent activity against Gram-positive and anaerobic pathogens.
- Ensures complete recovery in SSTIs
- Provides excellent outcome in odontogenic infections.
- Ensures quick recovery in diabetic foot infection.